Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 1 client • 8 examiners • 6 art units • 0 of 8 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Clark+Elbing LLP - Moderna focuses on Biotechnology & Pharmaceuticals and has 8 pending office actions. The profile also records 9010 career applications, providing portfolio context for the current unresolved matters.
The resolved allowance rate is 67.77%, and the average office actions per allowance is 3.89. These measures identify the recorded allowance outcome and the amount of examination activity associated with allowed matters. Practitioners can use them to frame prosecution planning while relying on the individual application record for claim and response decisions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (12%) |
| Double-patenting + other | 2 (25%) |
| Multi-statute (no §101) | 3 (38%) |
| No statute on record | 2 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KELLY, ROBERT M | 1 | 74.1% | +24.1% |
| SHIN, DANA H | 1 | 26.9% | +26.9% |
| HASAN, KHALEDA B | 1 | 59.3% | +49.0% |
| CARR, DEBORAH D | 1 | 81.8% | +2.9% |
| LEONARD, ARTHUR S | 1 | 50.5% | +50.4% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.7% |
| MCDOWELL, BRIAN E | 1 | 74.0% | +31.0% |
| JOHNSON, ALLISON MARIE | 1 | 40.9% | +53.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18672502 | TERMINALLY MODIFIED RNA | KELLY, ROBERT M | — |
| 18592122 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | SHIN, DANA H | — |
| 18551704 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | CARR, DEBORAH D | — |
| 18161598 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | VANHORN, ABIGAIL LOUISE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17276983 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS | JOHNSON, ALLISON MARIE | 32d overdue |
| 18672502 | TERMINALLY MODIFIED RNA | KELLY, ROBERT M | — |
| 18592122 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | SHIN, DANA H | — |
| 18543930 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | HASAN, KHALEDA B | — |
| 18177455 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | LEONARD, ARTHUR S | — |
| 18161598 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | VANHORN, ABIGAIL LOUISE | — |
| 17277829 | STEROL ANALOGS AND USES THEREOF | MCDOWELL, BRIAN E | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Moderna | 8 |
| Art Unit | Apps |
|---|---|
| 1638 | 2 |
| 1636 | 2 |
| 1635 | 1 |
| 1691 | 1 |
| 1631 | 1 |
| 1624 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18672502 | TERMINALLY MODIFIED RNA | Modernatx, Inc. | KELLY, ROBERT M | 1638 | §102§112Other | Non-Final OA | — | Pending | May 23, 2024 |
| 18592122 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | Modernatx, Inc. | SHIN, DANA H | 1635 | §112DP | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18543930 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | Modernatx, Inc. | HASAN, KHALEDA B | 1636 | Other | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18551704 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | Modernatx, Inc. | CARR, DEBORAH D | 1691 | §102§103§112 | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18177455 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | Modernatx, Inc. | LEONARD, ARTHUR S | 1631 | §103§112DPOther | Non-Final OA | — | Pending | Mar 02, 2023 |
| 18161598 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | Modema Tx, Inc. | VANHORN, ABIGAIL LOUISE | 1636 | §103§112Other | Non-Final OA | — | Pending | Jan 30, 2023 |
| 17277829 | STEROL ANALOGS AND USES THEREOF | Modernatx, Inc. | MCDOWELL, BRIAN E | 1624 | Other | Non-Final OA | — | Pending | Mar 19, 2021 |
| 17276983 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS | Modernatx, Inc. | JOHNSON, ALLISON MARIE | 1638 | §103 | Final Rejection | 32d overdue | Pending | Mar 17, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial67.8% of resolved applications prosecuted by Clark+Elbing LLP - Moderna were allowed, across 9,010 applications in USPTO records.
3.89 office actions per allowed application on average.
8 pending office actions as of October 2026, for 1 client, before 8 examiners in 6 art units.
